louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06348758: Knowledge, Attitudes, And Perceptions of a Group of Egyptian Dental Students Towards Artificial Intelligence
Official title: Knowledge, Attitudes, And Perceptions of a Group of Egyptian Dental Students Towards Artificial Intelligence: A Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Health Knowledge, Attitudes, Practice
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-04-05
Enrollment: 384
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Dental students in Egypt

Brief summary: In the context of this ongoing AI revolution, it is essential to ensure that current and future clinical practitioners are up to date regarding this technology's current state and potential. It is valuable to assess the current attitude of clinical dentists and undergraduate students in dentistry regarding the future role of AI.

To the best of the author's knowledge, there is no study about Egyptian dental students' views and attitudes regarding the application of AI in dental practice. Therefore, this study aimed to evaluate the attitudes and perceptions of a group of dental students in Egypt towards AI.

Detailed description: Data will be collected using a questionnaire. The survey will be distributed to dental students at the Faculty of Dentistry, Cairo, and Egyptian Russian universities through Google Forms. The questionnaire comprised 3 sections and 22 questions. The survey consisted of a question on demographics and educational information about dental students, knowledge of and attitudes towards AI, future application areas of AI in dentistry, and topics of AI in dental education. The first part of the survey. Informed consent will be obtained from all the participants before completing the questionnaire.

Eligibility criteria: Inclusion Criteria:

- Dental students

Exclusion Criteria:

* Graduates

Primary outcomes:
measure: knowledge, attitudes, and perceptions about artificial intelligence in Dentistry
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University- Faculty of Dentistry
Study officials:
affiliation: Cairo University
name: Reem Wahby, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00129558: A Study to Evaluate PT-523 in Patients With Refractory Leukemia
Official title: A Phase I/II Study of PT-523 in Patients With Refractory Leukemia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Leukemia
Lead sponsor: Spectrum Pharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2005-08-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: This Phase I/II, multi-centered, non-randomized, trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with refractory leukemia.


Eligibility criteria: Inclusion Criteria:

* Relapsed/refractory leukemias including acute non-lymphocytic leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia in blastic phase (CML-BP) for which no standard therapies are anticipated to result in a durable remission; or poor-risk myelodysplasia (MDS) patients to include refractory anemia with excess blasts (RAEB) or excess blasts in transformation (RAEBT) and chronic myelomonocytic leukemia (CMML) who are either relapsed/refractory or who refuse/are not eligible for frontline therapy.
* Only patients with refractory ALL or CML in lymphoid blastic phase are eligible for phase II.
* ECOG performance status 0 - 2.
* Adequate organ function and bone marrow reserve.
* At least 4 weeks must have elapsed from the time of major surgery.
* Use of appropriate contraceptive method.
* Signed patient informed consent.

Exclusion Criteria:

* Known human immunodeficiency virus (HIV).
* Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure.
* Patients receiving any other standard or investigational treatment for their leukemia other than corticosteriods, hydroxyurea, and 6-mercaptopurine.
* Any medical condition which, in the opinion of the investigator, places the patient at an unacceptably high risk for toxicities.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC, Kennth Norris Jr. Comprehensive Cancer Center
state: California
city: Los Angeles
country: United States
facility: UCLA School of Medicine
state: California
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Winston-Salem
country: United States
facility: Wake Forest University School of Medicine Comprehensive Cancer Center
state: North Carolina
city: Houston
country: United States
facility: University of Texas M. D. Anderson Cancer Center
state: Texas
Study officials:
References:
Clinical trial NCT05095558: Microtransplantation for Ovarian Cancer
Official title: Microtransplantation for Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Ovarian Cancer Recurrent
Keywords: microtransplantation
Lead sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Sponsor class: OTHER
First posted: 2021-10-27
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study, we will apply micro transplantation to the field of recurrent and advanced ovarian cancer to study the efficacy and safety.

Detailed description: The eligible patients are assigned to the experimental group (microtransplantation group, MST group) or the control group (CT) according to the availability of suitable donors. In MST group, peripheral blood hematopoietic stem cells from HLA mismatched donors mobilized with granulocyte colony stimulating factor are infused after conventional chemotherapy and/or radiotherapy ; The CT group only received conventional chemotherapy and/or radiotherapy. According to the patient's past medical history, current tumor assessment results, and the latest cancer treatment guidelines, the individualized chemotherapy and / or radiotherapy plan for the patient is formulated after discussion by more than 3 oncologists. After each course of treatment, the efficacy and safety are evaluated. For the patients who are evaluated to be effective or stable (SD) after the first treatment, the second treatment of the same scheme will be given. Those who reach the disease control level will continue to be treated for 4 courses, with an interval of 28 days. The patients who failed to achieve the improvement of SD after two cycles of chemotherapy will be withdrawn from the study. Patients are allowed to receive any treatment, including symptomatic support treatment, after the end of treatment or withdrawal from the study.

Eligibility criteria: Inclusion Criteria:

* Patients are 18-80 years old, female，regardless of race;
* Advanced / relapsed ovarian cancer confirmed by clinical or histopathological diagnosis;
* More than two kinds of tumors are allowed;
* Karnofsky score ≥ 60, ECoG physical status ≤ 2;
* Sensitive to chemotherapy or radiotherapy;
* There are measurable lesions;
* There are suitable hematopoietic stem cell donors

Exclusion Criteria:

* have no suitable donor or donor refused
* patient refused to accept donor cells

Primary outcomes:
measure: Treatment-Emergent Adverse Events
timeFrame: 1 month
measure: time of hematopoietic recovery
timeFrame: 1 month
Secondary outcomes:
measure: overall response rate
timeFrame: 1year
Other outcomes:
Locations:
city: Beijing
country: China
facility: The third medical center of PLA General Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT06936358: Injectable Platelet-rich Fibrin and Advanced Platelet-rich Fibrin With Xenograft on the Socket Preservation of Mandibular Extracted Molars
Official title: Comparison of the Effect of Injectable Platelet-rich Fibrin and Advanced Platelet-rich Fibrin With Xenograft on the Socket Preservation of Mandibular Extracted Molars ( a Randomised Controlled Clinical Trial) Comparison of the Effect of Injectable Platelet-rich Fibrin and Advanced Platelet-rich Fibrin With Xenograft on the Socket Preservation of Mandibular Extracted Molars ( a Randomised Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tooth Extraction
Socket Preservation
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-04-20
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Different materials and techniques are employed for socket preservation to reduce the alveolar bone resorption in both the horizontal and vertical dimensions as well as the soft tissue collapse after tooth extraction. Because of the repair abilities of the growth factors and proteins released by platelets, the development and application of platelet-enriched preparations have revolutionised the area of regenerative medicine.The present study will be designed to study the difference between A-PRF and IPRF with the addition of Xenograft in the preservation of bone in mandibular molars.


Eligibility criteria: Inclusion Criteria:

* Patients who need extraction of hopeless mandibular molars
* Teeth with advanced caries not amenable for conservative treatment
* Patients who are willing and fully capable of complying with the study protocol.

Exclusion Criteria:

* Systemic diseases that prevent surgery
* Acute or chronic oral infections
* Periodontal diseases
* Heavy smokers or alcoholics
* On anticoagulant drugs.
* Pregnancy
* History of radiotherapy or chemotherapy of the head and neck region

Primary outcomes:
measure: Change in healing
timeFrame: Baseline and 12 weeks
measure: change in bone density
timeFrame: Baseline and 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University
Study officials:
References:
Clinical trial NCT04184258: Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells
Official title: Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem Cells
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Systemic Lupus Erythematosus
Keywords: Systemic Lupus Erythematosus
mesenchymal stem cells
Lead sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Sponsor class: OTHER_GOV
Collaborators: name: Belarusian State Medical University
First posted: 2019-12-03
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells


Eligibility criteria: Inclusion Criteria:

* SLE diagnosis (4 of 11 criteria by ACR);
* positive dsDNA;
* SELENA-SLEDAI index ≥6;
* active lupus nephritis;
* patient can read, understand and follow the procedures.

Exclusion Criteria:

* need for dialysis;
* planned renal transplantation;
* any medical condition which can be associated with the high risk for the patient;
* pregnancy/lactation;
* chronic infections, including hepatitis B/C, tuberculosis, HIV;
* any malignant tumor in the last 5 years.

Primary outcomes:
measure: Efficacy evaluation
timeFrame: 6 month
Secondary outcomes:
measure: Safety eveluation
timeFrame: 1 month
Other outcomes:
Locations:
city: Minsk
country: Belarus
facility: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Study officials:
affiliation: Director, the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
name: Andrei Hancharou, Dr
role: STUDY_DIRECTOR
affiliation: Associate professor, Belarusian State Medical University
name: Konstantin A Chizh, Dr
role: STUDY_DIRECTOR
References:
Clinical trial NCT02724358: Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
TACE
Notch1
Rg3
Keywords: Carcinoma
Hepatocellular
Notch1
Lead sponsor: Eastern Hepatobiliary Surgery Hospital
Sponsor class: OTHER
First posted: 2016-03-31
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.


Eligibility criteria: Inclusion Criteria:

1. Pathologically confirmed hepatocellular carcinoma.
2. High expression of Notch1 in tumor tissues.

Exclusion Criteria:

no pathological evidence of HCC

Primary outcomes:
measure: Overall Survival
timeFrame: 3 years
measure: Time to progression
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Eastern hepatobilliary surgery hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT02218658: Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males
Official title: The Bioequivalence Between WE 941 OD Tablets (0.25mg as the Basis) Taken Without Water and Brotizolam Conventional Tablets (Lendormin® Tablets, 0.25 mg as the Basis) Taken With Water, as a Single Administration in Healthy Adult Male Subjects (Open-labelled, 2-way Cross-over Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-08-18
Enrollment: 30
Sex: MALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The bioequivalence of WE 941 OD tablets prepared in oral disintegrating tablet form taken without water and brotizolam conventional tablets (Lendormin® tablets) taken with water, was evaluated in healthy adult male subjects (open-labelled, 2-way cross-over study)


Eligibility criteria: Inclusion Criteria:

* Age between 20 and 35 years
* Weight between 50 and 80 kg
* Obesity level within the range of +/- 20% of the standard weight according to the Body Mass Index (BMI) method
* Judged as eligible as a study object following the screening test by the investigator
* Volunteers to participate in the study, who are capable of giving written informed consent

Exclusion Criteria:

* Known hypersensitivity to drugs
* History of drug or alcohol abuse
* Received other investigational drug within 4 months of the trial drug administration
* Had \> 400 mL of whole blood drawn within 3 months of the trial drug administration
* Had \> 400 mL of blood components drawn within 1 month of the trial drug administration
* Used any drug within 10 days of the trial drug administration
* Engaged in strenuous exercise within 5 days of the trial drug administration
* Consumed alcohol within 3 days of the trial drug administration
* Judged as ineligible for the study participation by the investigator for a reason other than above

Primary outcomes:
measure: AUC0-24h (Area under the plasma concentration-time from 0 to 24 hours)
timeFrame: up to 24 hours after drug administration
measure: Cmax (maximum plasma concentration)
timeFrame: up to 24 hours after drug administration
Secondary outcomes:
measure: Number of patients with adverse events
timeFrame: up to 30 days
measure: tmax (time to maximum plasma concentration)
timeFrame: up to 24 hours after drug administration
measure: MRT (Mean residence time)
timeFrame: up to 24 hours after drug administration
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02699658: Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Healthy Volunteers
Keywords: levofloxacin
population pharmacokinetics
pharmacodynamics
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
First posted: 2016-03-04
Enrollment: 45
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Levofloxacin, a fluoroquinolone antibiotic, is the optical S-(-) isomer of ofloxacin with a broad spectrum of activity. In common with other fluoroquinolones, the main pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with its therapeutic efficacy is the area under the plasma time-concentration curve/the minimum inhibitory concentration ratios.

The aims of the study were to:

1. reveal the population pharmacokinetics, and
2. assess the efficacy of various dosage regimens in achieving the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of levofloxacin when oral levofloxacin was prescribed as the switching therapy after intravenous levofloxacin treatment.

The study was conducted in 45 healthy volunteers. Each subject received one 500 mg tablet of levofloxacin, after which PK studies were carried out, using a Monte Carlo simulation to determine the PTA. By referral to the EUCAST MIC distributions database, the dosage regimens were predicted to achieve CFR greater than or equal to 90%.


Eligibility criteria: Inclusion:

* normal hematologic
* normal hepatic
* normal renal functions
* non-smoking
* non-alcoholic
* non-obese

Exclusion:

* pregnant or lactating women
* any chronic medications

Primary outcomes:
measure: concentration of levofloxacin in plasma
timeFrame: up to 2 week after blood collection
Secondary outcomes:
Other outcomes:
Locations:
city: Hat Yai
country: Thailand
facility: Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University
state: Songkla
Study officials:
References:
Clinical trial NCT01103258: FOAM-study, Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins
Official title: FOAM-study Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Varicose Vein Disease
Keywords: Incompetence of the great saphenous vein.
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
Collaborators: name: ZonMw: The Netherlands Organisation for Health Research and Development
First posted: 2010-04-14
Enrollment: 460
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Varicose vein disease is a common health problem, which causes much discomfort to patients.

Nowadays treatment modalities for greater saphenous veins include surgery and duplex guided foam sclerotherapy. These are two equally accepted and applied treatments for the same patient population.

Choice of treatment often depends on the referral preference of the General Practitioner. Until now data are missing which treatment is more cost effective. The current proposal aims at comparing the effects, costs and patient preferences between duplex guided foam sclerotherapy and surgery in the treatment of greater varicose veins.


Eligibility criteria: Inclusion Criteria:

* incompetence of great saphenous vein for minimal 20 cm
* life expectancy at least 3 years
* open and competent deep venous system
* willing to undergo both treatments

Exclusion Criteria:

* active ulcer
* signs of deep venous thrombosis with duplex
* incompetence of the deep venous system

Primary outcomes:
measure: cumulative probability of recurrent varicose vein within 24 months after treatment
timeFrame: 24 months
Secondary outcomes:
measure: quality of life (as measured by EuroQol-5D)
timeFrame: 24 months
measure: patient preferences (as measured by conjoint analysis)
timeFrame: 24 months
measure: direct Health care costs
timeFrame: 24 months
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht UMC
Study officials:
affiliation: Maastricht UMC
name: A Sommer, MD PhD
role: STUDY_DIRECTOR
References:
citation: Shadid N, Ceulen R, Nelemans P, Dirksen C, Veraart J, Schurink GW, van Neer P, vd Kley J, de Haan E, Sommer A. Randomized clinical trial of ultrasound-guided foam sclerotherapy versus surgery for the incompetent great saphenous vein. Br J Surg. 2012 Aug;99(8):1062-70. doi: 10.1002/bjs.8781. Epub 2012 May 25.
Clinical trial NCT01497158: Promoting Home Smoking Restrictions: Biomarker Feedback to Smoking and Non-Smoking Adults
Official title: Promoting Home Smoking Restrictions: Biomarker Feedback to Cohabitating Smoking and Non-Smoking Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking Cessation
Tobacco Use Disorder
Keywords: tobacco cessation
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2011-12-22
Enrollment: 122
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is directed at decreasing home environmental tobacco smoking (ETS) exposure with a novel approach of adoption of home smoking restrictions. This will be done by providing the cohabitating smoker and non-smoker with biomarker feedback documenting exposure to ETS. The intent is to identify an intervention strategy(ies) to reduce ETS exposure.

Detailed description: This is a two-group interventional trial targeting cohabitating smokers and non-smokers. Participants will be randomized to the control condition or biomarker feedback group.

Eligibility criteria: Inclusion Criteria:

* Must be at least 18 years of age
* Cohabitating Non-Smoker (control) and smoker (active)
* Smoker must test \> 6ppm on carbon dioxide (CO) test and non-smoker \< 6ppm
* General good health
* Written informed consent
* Live within Twin Cities 7 county metropolitan area (Minnesota)
* Plan to live in same home for 6 months and be willing for researchers to come to their home

Exclusion Criteria:

* Individuals that live in a treatment facility or shelter
* Individuals endorsing current domestic violence

Primary outcomes:
measure: Comparison of Self-Reported Home Smoking Restrictions - Active Counseling
timeFrame: From baseline to week 12
measure: Comparison of Self-Reported Home Smoking Restrictions - Control Group
timeFrame: From baseline to week 12
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Janet Thomas, M.D.
role: PRINCIPAL_INVESTIGATOR
References: